ChloroquineV1, Main, Exploration, bibRecord, 000F03

Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.

Identifieur interne : 000F03 ( Main/Exploration ); précédent : 000F02; suivant : 000F04

Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.

Auteurs : Jia-Tao Liu [République populaire de Chine] ; Wen-Cheng Li [République populaire de Chine] ; Shuang Gao [République populaire de Chine] ; Fang Wang [République populaire de Chine] ; Xiao-Qiu Li [République populaire de Chine] ; Han-Qing Yu [République populaire de Chine] ; Lu-Lu Fan [République populaire de Chine] ; Wei Wei [République populaire de Chine] ; Hua Wang [République populaire de Chine] ; Guo-Ping Sun [République populaire de Chine]

Source :

Clinical lung cancer [ 1938-0690 ] ; 2015.

RBID : pubmed:25979647

Descripteurs français

English descriptors

KwdEn :
- Antineoplastic Combined Chemotherapy Protocols (administration & dosage), Antineoplastic Combined Chemotherapy Protocols (pharmacology), Apoptosis (drug effects), Autophagy (drug effects), Carcinoma, Non-Small-Cell Lung (drug therapy), Carcinoma, Non-Small-Cell Lung (genetics), Carcinoma, Non-Small-Cell Lung (pathology), Cell Line, Tumor, Cell Proliferation (drug effects), Chloroquine (pharmacology), Cisplatin (administration & dosage), Cisplatin (pharmacology), Drug Synergism, ErbB Receptors (genetics), Gefitinib, Humans, Lung Neoplasms (drug therapy), Lung Neoplasms (genetics), Lung Neoplasms (pathology), Mutation, Protein Kinase Inhibitors (administration & dosage), Protein Kinase Inhibitors (pharmacology), Quinazolines (administration & dosage), Quinazolines (pharmacology).
MESH :
- chemical , administration & dosage : Cisplatin, Protein Kinase Inhibitors, Quinazolines.
- chemical , genetics : ErbB Receptors.
- chemical , pharmacology : Chloroquine, Cisplatin, Protein Kinase Inhibitors, Quinazolines.
- administration & dosage : Antineoplastic Combined Chemotherapy Protocols.
- drug effects : Apoptosis, Autophagy, Cell Proliferation.
- drug therapy : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- genetics : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- pathology : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- pharmacology : Antineoplastic Combined Chemotherapy Protocols.
- Cell Line, Tumor, Drug Synergism, Gefitinib, Humans, Mutation.

Abstract

Four large clinical trials have shown that concurrent administration of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), such as gefitinib or erlotinib, with chemotherapy agents does not improve overall survival (OS) in unselected patients with advanced non-small-cell lung cancer (NSCLC). In the present study, the role of autophagy in the combination of gefitinib and cisplatin on EGFR-TKI-sensitive human lung cancer cell line was investigated. Moreover, whether simultaneous autophagy inhibition treatment increases the antitumor activity was explored.

DOI: 10.1016/j.cllc.2015.03.006
PubMed: 25979647

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.</title>
<author><name sortKey="Liu, Jia Tao" sort="Liu, Jia Tao" uniqKey="Liu J" first="Jia-Tao" last="Liu">Jia-Tao Liu</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei</wicri:regionArea>
<placeName><settlement type="city">Hefei</settlement>
<region type="province">Anhui</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Li, Wen Cheng" sort="Li, Wen Cheng" uniqKey="Li W" first="Wen-Cheng" last="Li">Wen-Cheng Li</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei</wicri:regionArea>
<placeName><settlement type="city">Hefei</settlement>
<region type="province">Anhui</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gao, Shuang" sort="Gao, Shuang" uniqKey="Gao S" first="Shuang" last="Gao">Shuang Gao</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei</wicri:regionArea>
<placeName><settlement type="city">Hefei</settlement>
<region type="province">Anhui</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wang, Fang" sort="Wang, Fang" uniqKey="Wang F" first="Fang" last="Wang">Fang Wang</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei</wicri:regionArea>
<placeName><settlement type="city">Hefei</settlement>
<region type="province">Anhui</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Li, Xiao Qiu" sort="Li, Xiao Qiu" uniqKey="Li X" first="Xiao-Qiu" last="Li">Xiao-Qiu Li</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei</wicri:regionArea>
<placeName><settlement type="city">Hefei</settlement>
<region type="province">Anhui</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yu, Han Qing" sort="Yu, Han Qing" uniqKey="Yu H" first="Han-Qing" last="Yu">Han-Qing Yu</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei</wicri:regionArea>
<placeName><settlement type="city">Hefei</settlement>
<region type="province">Anhui</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fan, Lu Lu" sort="Fan, Lu Lu" uniqKey="Fan L" first="Lu-Lu" last="Fan">Lu-Lu Fan</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei</wicri:regionArea>
<placeName><settlement type="city">Hefei</settlement>
<region type="province">Anhui</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wei, Wei" sort="Wei, Wei" uniqKey="Wei W" first="Wei" last="Wei">Wei Wei</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute of Clinical Pharmacology, Anhui Medical University, Hefei, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Institute of Clinical Pharmacology, Anhui Medical University, Hefei</wicri:regionArea>
<placeName><settlement type="city">Hefei</settlement>
<region type="province">Anhui</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wang, Hua" sort="Wang, Hua" uniqKey="Wang H" first="Hua" last="Wang">Hua Wang</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei</wicri:regionArea>
<placeName><settlement type="city">Hefei</settlement>
<region type="province">Anhui</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sun, Guo Ping" sort="Sun, Guo Ping" uniqKey="Sun G" first="Guo-Ping" last="Sun">Guo-Ping Sun</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China. Electronic address: sungp@ahmu.edu.cn.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei</wicri:regionArea>
<placeName><settlement type="city">Hefei</settlement>
<region type="province">Anhui</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25979647</idno>
<idno type="pmid">25979647</idno>
<idno type="doi">10.1016/j.cllc.2015.03.006</idno>
<idno type="wicri:Area/PubMed/Corpus">000250</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000250</idno>
<idno type="wicri:Area/PubMed/Curation">000250</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000250</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000258</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000258</idno>
<idno type="wicri:Area/Ncbi/Merge">000295</idno>
<idno type="wicri:Area/Ncbi/Curation">000295</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000295</idno>
<idno type="wicri:Area/Main/Merge">000F04</idno>
<idno type="wicri:Area/Main/Curation">000F03</idno>
<idno type="wicri:Area/Main/Exploration">000F03</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.</title>
<author><name sortKey="Liu, Jia Tao" sort="Liu, Jia Tao" uniqKey="Liu J" first="Jia-Tao" last="Liu">Jia-Tao Liu</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei</wicri:regionArea>
<placeName><settlement type="city">Hefei</settlement>
<region type="province">Anhui</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Li, Wen Cheng" sort="Li, Wen Cheng" uniqKey="Li W" first="Wen-Cheng" last="Li">Wen-Cheng Li</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei</wicri:regionArea>
<placeName><settlement type="city">Hefei</settlement>
<region type="province">Anhui</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gao, Shuang" sort="Gao, Shuang" uniqKey="Gao S" first="Shuang" last="Gao">Shuang Gao</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei</wicri:regionArea>
<placeName><settlement type="city">Hefei</settlement>
<region type="province">Anhui</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wang, Fang" sort="Wang, Fang" uniqKey="Wang F" first="Fang" last="Wang">Fang Wang</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei</wicri:regionArea>
<placeName><settlement type="city">Hefei</settlement>
<region type="province">Anhui</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Li, Xiao Qiu" sort="Li, Xiao Qiu" uniqKey="Li X" first="Xiao-Qiu" last="Li">Xiao-Qiu Li</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei</wicri:regionArea>
<placeName><settlement type="city">Hefei</settlement>
<region type="province">Anhui</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yu, Han Qing" sort="Yu, Han Qing" uniqKey="Yu H" first="Han-Qing" last="Yu">Han-Qing Yu</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei</wicri:regionArea>
<placeName><settlement type="city">Hefei</settlement>
<region type="province">Anhui</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fan, Lu Lu" sort="Fan, Lu Lu" uniqKey="Fan L" first="Lu-Lu" last="Fan">Lu-Lu Fan</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei</wicri:regionArea>
<placeName><settlement type="city">Hefei</settlement>
<region type="province">Anhui</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wei, Wei" sort="Wei, Wei" uniqKey="Wei W" first="Wei" last="Wei">Wei Wei</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute of Clinical Pharmacology, Anhui Medical University, Hefei, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Institute of Clinical Pharmacology, Anhui Medical University, Hefei</wicri:regionArea>
<placeName><settlement type="city">Hefei</settlement>
<region type="province">Anhui</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wang, Hua" sort="Wang, Hua" uniqKey="Wang H" first="Hua" last="Wang">Hua Wang</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei</wicri:regionArea>
<placeName><settlement type="city">Hefei</settlement>
<region type="province">Anhui</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sun, Guo Ping" sort="Sun, Guo Ping" uniqKey="Sun G" first="Guo-Ping" last="Sun">Guo-Ping Sun</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China. Electronic address: sungp@ahmu.edu.cn.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei</wicri:regionArea>
<placeName><settlement type="city">Hefei</settlement>
<region type="province">Anhui</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Clinical lung cancer</title>
<idno type="eISSN">1938-0690</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols (administration & dosage)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (pharmacology)</term>
<term>Apoptosis (drug effects)</term>
<term>Autophagy (drug effects)</term>
<term>Carcinoma, Non-Small-Cell Lung (drug therapy)</term>
<term>Carcinoma, Non-Small-Cell Lung (genetics)</term>
<term>Carcinoma, Non-Small-Cell Lung (pathology)</term>
<term>Cell Line, Tumor</term>
<term>Cell Proliferation (drug effects)</term>
<term>Chloroquine (pharmacology)</term>
<term>Cisplatin (administration & dosage)</term>
<term>Cisplatin (pharmacology)</term>
<term>Drug Synergism</term>
<term>ErbB Receptors (genetics)</term>
<term>Gefitinib</term>
<term>Humans</term>
<term>Lung Neoplasms (drug therapy)</term>
<term>Lung Neoplasms (genetics)</term>
<term>Lung Neoplasms (pathology)</term>
<term>Mutation</term>
<term>Protein Kinase Inhibitors (administration & dosage)</term>
<term>Protein Kinase Inhibitors (pharmacology)</term>
<term>Quinazolines (administration & dosage)</term>
<term>Quinazolines (pharmacology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Apoptose ()</term>
<term>Autophagie ()</term>
<term>Carcinome pulmonaire non à petites cellules (anatomopathologie)</term>
<term>Carcinome pulmonaire non à petites cellules (génétique)</term>
<term>Carcinome pulmonaire non à petites cellules (traitement médicamenteux)</term>
<term>Chloroquine (pharmacologie)</term>
<term>Cisplatine (administration et posologie)</term>
<term>Cisplatine (pharmacologie)</term>
<term>Humains</term>
<term>Inhibiteurs de protéines kinases (administration et posologie)</term>
<term>Inhibiteurs de protéines kinases (pharmacologie)</term>
<term>Lignée cellulaire tumorale</term>
<term>Mutation</term>
<term>Prolifération cellulaire ()</term>
<term>Protocoles de polychimiothérapie antinéoplasique (administration et posologie)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (pharmacologie)</term>
<term>Quinazolines (administration et posologie)</term>
<term>Quinazolines (pharmacologie)</term>
<term>Récepteurs ErbB (génétique)</term>
<term>Synergie des médicaments</term>
<term>Tumeurs du poumon (anatomopathologie)</term>
<term>Tumeurs du poumon (génétique)</term>
<term>Tumeurs du poumon (traitement médicamenteux)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Cisplatin</term>
<term>Protein Kinase Inhibitors</term>
<term>Quinazolines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>ErbB Receptors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Chloroquine</term>
<term>Cisplatin</term>
<term>Protein Kinase Inhibitors</term>
<term>Quinazolines</term>
</keywords>
<keywords scheme="MESH" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Cisplatine</term>
<term>Inhibiteurs de protéines kinases</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
<term>Quinazolines</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Apoptosis</term>
<term>Autophagy</term>
<term>Cell Proliferation</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term>
<term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term>
<term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term>
<term>Récepteurs ErbB</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term>
<term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Chloroquine</term>
<term>Cisplatine</term>
<term>Inhibiteurs de protéines kinases</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
<term>Quinazolines</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacology" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Cell Line, Tumor</term>
<term>Drug Synergism</term>
<term>Gefitinib</term>
<term>Humans</term>
<term>Mutation</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Apoptose</term>
<term>Autophagie</term>
<term>Humains</term>
<term>Lignée cellulaire tumorale</term>
<term>Mutation</term>
<term>Prolifération cellulaire</term>
<term>Synergie des médicaments</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Four large clinical trials have shown that concurrent administration of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), such as gefitinib or erlotinib, with chemotherapy agents does not improve overall survival (OS) in unselected patients with advanced non-small-cell lung cancer (NSCLC). In the present study, the role of autophagy in the combination of gefitinib and cisplatin on EGFR-TKI-sensitive human lung cancer cell line was investigated. Moreover, whether simultaneous autophagy inhibition treatment increases the antitumor activity was explored.</div>
</front>
</TEI>
<affiliations><list><country><li>République populaire de Chine</li>
</country>
<region><li>Anhui</li>
</region>
<settlement><li>Hefei</li>
</settlement>
</list>
<tree><country name="République populaire de Chine"><region name="Anhui"><name sortKey="Liu, Jia Tao" sort="Liu, Jia Tao" uniqKey="Liu J" first="Jia-Tao" last="Liu">Jia-Tao Liu</name>
</region>
<name sortKey="Fan, Lu Lu" sort="Fan, Lu Lu" uniqKey="Fan L" first="Lu-Lu" last="Fan">Lu-Lu Fan</name>
<name sortKey="Gao, Shuang" sort="Gao, Shuang" uniqKey="Gao S" first="Shuang" last="Gao">Shuang Gao</name>
<name sortKey="Li, Wen Cheng" sort="Li, Wen Cheng" uniqKey="Li W" first="Wen-Cheng" last="Li">Wen-Cheng Li</name>
<name sortKey="Li, Xiao Qiu" sort="Li, Xiao Qiu" uniqKey="Li X" first="Xiao-Qiu" last="Li">Xiao-Qiu Li</name>
<name sortKey="Sun, Guo Ping" sort="Sun, Guo Ping" uniqKey="Sun G" first="Guo-Ping" last="Sun">Guo-Ping Sun</name>
<name sortKey="Wang, Fang" sort="Wang, Fang" uniqKey="Wang F" first="Fang" last="Wang">Fang Wang</name>
<name sortKey="Wang, Hua" sort="Wang, Hua" uniqKey="Wang H" first="Hua" last="Wang">Hua Wang</name>
<name sortKey="Wei, Wei" sort="Wei, Wei" uniqKey="Wei W" first="Wei" last="Wei">Wei Wei</name>
<name sortKey="Yu, Han Qing" sort="Yu, Han Qing" uniqKey="Yu H" first="Han-Qing" last="Yu">Han-Qing Yu</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F03 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F03 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:25979647
   |texte=   Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:25979647" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a ChloroquineV1

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

Serveur d'exploration Chloroquine

Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.

Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.